Role of hyperbaric oxygen exposure in reduction of lipid peroxidation and in multiple organ failure induced by zymosan administration in the rat

Shock

Volumn 13, Issue 3, 2000, Pages 197-203

  Cuzzocrea, Salvatore ^c   Imperatore, Francesco ^a   Costantino, Giuseppina ^d   Luongo, Carlo ^a   Mazzon, Emanuela ^d   Scafuro, Maria Antonietta ^a   Mangoni, Giuseppe ^a   Caputi, Achille P ^d   Rossi, Francesco ^a   Filippelli, Amelia ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF CALABRIA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d NONE

Author keywords

Hyperbaric oxygen therapy; Nitric oxide; Peritonitis; Shock; Tumor necrosis factor alpha; Zymosan

Indexed keywords

3 NITROTYROSINE; 3-NITROTYROSINE; DRUG DERIVATIVE; MALONALDEHYDE; PEROXIDASE; TYROSINE; ZYMOSAN;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HYPERBARIC OXYGEN; LIPID PEROXIDATION; MALE; METABOLISM; MULTIPLE ORGAN FAILURE; PATHOLOGY; PERITONITIS; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; HYPERBARIC OXYGENATION; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MULTIPLE ORGAN FAILURE; PERITONITIS; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE; ZYMOSAN;

EID: 0034146022     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200003000-00005     Document Type: Article

References (45)

1. Faist E, Baue AE, Dittmer H, Heberer G: Multiple organ failure in polytrauma patients. J Trauma 23:775-787, 1983.
2. Shayevitz JR, Miller C, Johnson KJ, Rodriguez JL: Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of nonseptic origin. Shock 4:389-396, 1995.
3. Goris RJA, Van Bebber, IPT, Mollen RMH, Koopman JP: Dose selective decontamination of the gastrointestinal tract prevent multiple organ failure? Arch Surg 126:561-565, 1991.
4. Demling R, Nayak U, Ikegami K, LaLonde C: Comparison between lung and liver peroxidation and mortality after zymosan peritonitis in the rats. Shock 2:222-227, 1994.
5. Van Bebber IPT, Boekholz KF, Goris RJA, et al.: Neutrophil function and lipid peroxidation in rat model of multiple organ failure. J Surg Res 47:471-475, 1939.
6. Von Asmuth EJU, Maessen IG, Van der Linden CJ, Buurman WA: Tumor necrosis factor alpha (TNF?) and interleukin 6 in zymosan-induced shock model. Scand J Immunol 32:313-319, 1990.
7. Petit F, Bagby GJ, Lang CH: Tumor necrosis factor mediates zymosan induced increase in glucose flux and insulin resistance. Am J Physiol 268:E219-E228, 1995.
8. Damas J, Remacle-Volon G, Bourdon V: Platelet-activating factor and vascular effects of zymosan in rats. Eur J Pharmacol 231:231-236, 1993.
9. Deitch EA, Ma L, Berg RD, Specian RD: Protein malnutrition predisposes to inflammatory-induced gut-origin septic states. Ann Surg 221:560-568, 1990.
10. Cuzzocrea S, Zingarelli B, Sautebin L, et al.: Multiple organ failure following zymosan-induced peritonitis is mediated by nitric oxide. Shock 4:268-275, 1997.
11. Mainous MR, Ertel W, Chaudry IH, Deitch EA: The gut: a cytokine-generating organ in systemic inflammation? Shock 4:193-199, 1995.
12. Teixeira TJ, Williams PG, Hellewell PG: Role of prostaglandins and nitric oxide in acute inflammatory reactions in guinea-pig skin. Br J Pharmacol 110:416-422, 1993.
13. Cuzzocrea S, Zingarelli B, Calapai G, et al.: Zymosan-activated plasma induces paw oedema by nitric oxide and prostaglandin production. Life Sci 60:215-20, 1997.
14. Cuzzocrea S, Filippelli A, Zingarelli B, et al.: Role of nitric oxide in a non-septic shock model induced by zymosan in the rat. Shock 7:351-358, 1997.
15. Luongo C, Imperatore F, Cuzzocrea S, Filippelli A, Scafuro MA, Mangoni G, Portolano F, Rossi F: Effects of hyperbaric oxygen exposure on zymosan-induced shock model. Crit Care Med 26:1972-6, 1998.
16. Leach RM, Rees PJ, Wilmshurst P. Hyperbaric oxygen therapy. BMJ 317:1140-1143, 1998.
17. Rachmilewitz D, Karmeli F, Okon E, et al. Hyperbaric oxygen: a novel modality to ameliorate experimental colitis. Gut 43:512-518, 1998.
18. Cuzzocrea S, Zingarelli B, Gilard E, et al.: Anti-inflammatory effects of mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, in carrageenan-induced models of inflammation. Free Rad Biol Med 24:450-459, 1998.
19. Mullane KM, Westlin W, Kraemer R: Activated neutrophils release mediators that may contribute to myocardial injury and dysfunction associated with ischemia and reperfusion. Ann NY Acad Sci 524:103-121, 1988.
20. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358, 1979.
21. Vane J, Botting R: Inflammation and the mechanism of action of antiinflammatory drugs. FASEB J 1:89-96, 1987.
22. Salvemini D, Wang ZQ, Wyatt P, et al.: Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol 118:829-832, 1996.
23. Salvemini D, Wang ZQ, Bourdon DM, et al.: Evidence of peroxynitrite involvement in the carrageenan-induced rat paw oedema. Eur J Pharmacol 303:217-220, 1996.
24. Cuzzocrea S, Zingarelli B, O'Connor M, et al.: Role of peroxynitrite and activation of Poly (ADP Ribose) Synthetase in the vascular failure induced by zymosan-activated plasma. Br J Pharmacol 122:493-503, 1997.
25. Halliwell B, Hoult JR, Blake DR: Oxidant inflammation and antiinflammatory drugs. FASEB J 2:2867-2873, 1988.
26. Maridonnean-Parini I, Clerc J, Polla BS.: Heat shock inhibits NADPH oxidase in human neutrophils. J Biol Chem 193:265-275, 1988.
27. Beckman JS, Beckman TW, Chen, J, et al.: Apparent hydroxyl radical production by peroxynitrite: implication for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87:1620-1629, 1990.
28. Rubbo H, Radi R, Trujillo M, et al.: Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem 269:26066-26075, 1994.
29. Graham A, Hogg N, Kalyanaraman B, et al.: Peroxynitrite modification of low density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett 330:18-25, 1993.
30. Lancaster JR: Nitric oxide in cells. Am Sci 80:248-255, 1992.
31. Doherty NS, Beaver TH, Chan KY, et al.: The antinociceptive activity of paracetamol in zymosan-induced peritonitis in mice: the role of prostacyclin and reactive oxygen species. Br J Pharmacol 101:869-874, 1990.
32. Rao TS, Currie JL, Shaffer AF, et al.: In vivo characterization of zymosan-induced mouse peritoneal inflammation. J Pharmacol Exp Therap 269: 917-925, 1993.
33. Fernandez PM, Hensen A, Otani A, et al.: Chemotactic response to human C3a and C5a anaphylatoxins: Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo condition. J Immunol 120:109-115, 1978.
34. Snyderman J, Phillips F, Mergenhagen SE: Polymorphonuclear leukocyte chemotactic activity in rabbit serum and guinea pig serum treated with immune complexes. Evidence for C5a as the major chemotactic factor. Infect Immun 1:521-525, 1970.
35. Murohara T, Kugyyama K, Sugiyama S, et al.: Activated human polymorphonuclear leukocytes elicit endothelium-dependent contraction in isolated pig coronary arteries. J Cardiovasc Pharmacol 21:760-766, 1993.
36. Mehta JL, Lawson DL, Nicolini FA, et al.: Effects of activated polimorphonuclear leukocytes on vascular smooth muscle tone. Am J Physiol 261:H327-H334, 1991.
37. Beckman JS: Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 9:836-44, 1996.
38. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, Van Der Vliet A: Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391:393-397, 1998.
39. Pelaia P, Rocco M, De Blasi RA, et al: Assessment of lipid peroxidation in hyperbaric oxygen therapy . Protective role of N-acetylcysteine. Minerva Anestesiol 61:133-139, 1995.
40. Thom SR: Functional inhibition of leukocyte B2 integrins by hyperbaric oxygen in carbon monoxide-mediated brain injury in rats. Toxicol Appl Pharmacol 123:248-256, 1993.
41. Zamboni WA, Wong HP, Stephenson LL: Effect of hyperbaric oxygen on neutrophil concentration and pulmonary sequestration in reperfusion injury. Arch Surg 131:755-760, 1996.
42. Brenner I, Shepard RJ, Shek PN Immune function in hyperbaric environments, diving, and decompression. Undersea Hyperb Med 26:27-39, 1999.
43. Izawa K, Tsunoda T, Ura K: Hyperbaric Oxygen Therapy in the treatment of refractory peripancreatic abscesses associated with severe acute pancreatitis. Gastrenterol Jpn 28:284-291, 1993.
44. Wallace DJ, Silverman S, Goldestein J, et al: Use of hyperbaric oxygen in rheumatic disease : case report and critical analysis. Lupus 4:172-175, 1995.
45. Lahat N, Bitterman H, Yaniv N, et al : Exposure to hyperbaric oxygen induces tumor necrosis factor-alpha (TNFα) secretion from rat macrophages. Clin Exp Immunol 102:655-659, 1995.